Abstract

Objective - Ulcerative colitis is an inflammatory bowel disease usually affecting the innermost lining of the colon and rectum. Both corticosteroids and anti-inflammatory drugs are administrated as medical treatment for UC. However, these drugs, in addition to chemical side effects, impose exorbitant costs on patients. Therefore, extensive studies are underway to find new treatment approaches. This study aims to determine the effect of calcitriol-treated mesenchymal stem cells in the UC treatment. Material and Methods - This experimental study was performed on 50 Wistar rats with inducing ulcerative colitis model by 4 acetic acid. MSCs were isolated from rat bone marrow and proliferated in an appropriate medium. Bone marrow-derived mesenchymal stem cells were injected intraperitoneally. Symptom severity of this disease was evaluated using the factors, such as stool consistency, fecal blood and histopathological study of colon tissue. Furthermore, the levels of myeloperoxidase, nitric oxide and inflammatory cytokines like IL-1, IL6 and TNF-alpha were measured using ELISA technique. Results - The results showed that calcitriol-treated MSCs, significantly reduced the production of inflammatory cytokines including IL-1 (150.22 +/- 29.04)(P<0.01), IL-6 (681 +/- 56.20)(P<0.01), TNF-alpha (53.07 +/- 11.30)(P<0.01) and significantly decrease in level of NO (12.86 +/- 5.65)(P<0.01), MPO (0.175 +/- 0.024)(P<0.01) and the destruction of intestinal crypts compared to the control group (P<0.05). Conclusions - It seems that using calcitriol with MSCs has reduced the symptoms of UC in our experimental model. Due to their ease of isolation and expansion, MSCs can be used as an adjunctive therapy to improve the condition of patients with UC colitis.